



REVIEW ARTICLE

## Basic symptoms in schizophrenia, their clinical study and relevance in research<sup>☆</sup>

Salvador Miret <sup>a,b,\*</sup>, Mar Fatjó-Vilas <sup>b,c</sup>, Víctor Peralta <sup>d</sup>, Lourdes Fañanás <sup>b,c</sup>

<sup>a</sup> Servei de Salut Mental, Psiquiatria i Addicions, Hospital de Santa Maria, Institut de Recerca Biomèdica (IRB), Lleida, Spain

<sup>b</sup> Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain

<sup>c</sup> Departament de Biología Animal, Facultat de Biología, Universitat de Barcelona, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain

<sup>d</sup> Sección de Psiquiatría B, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain

Received 3 May 2015; accepted 29 October 2015

Available online 11 May 2016



CrossMark

### KEYWORDS

Basic symptoms;  
Schizophrenia;  
Prodromal phase;  
Phenomenology;  
Instruments

**Abstract** Basic symptoms consist of subtle sub-clinical disturbances subjectively experienced by schizophrenia patients. These are mainly related to drive, affect, thinking and language, perception, memory, motor action, central vegetative functions, control of cognitive processes, and stress tolerance. Initially described by Huber, from a phenomenological approach, basic symptoms are part of the earliest features of schizophrenia, and they can evolve along the course of the disorder. Their assessment during the prodromal phase of the disease (together with ultra-high risk criteria) is one of the 2 main approaches that allow the definition of states of clinical risk for the development of psychosis. The present review provides an updated view of the concept of basic symptoms, highlighting its potential value in establishing neurobiological correlates of interest in aetiopathogenic research.

© 2015 SEP y SEPB. Published by Elsevier España, S.L.U. All rights reserved.

### PALABRAS CLAVE

Síntomas básicos;  
Esquizofrenia;  
Fase prodrómica;  
Fenomenología;  
Instrumentos

**Síntomas básicos en la esquizofrenia, su estudio clínico y relevancia en investigación**

**Resumen** Los síntomas básicos consisten en sutiles molestias subclínicas, experimentadas subjetivamente por el paciente, principalmente referidas a la volición, la afectividad, el pensamiento y lenguaje, la percepción, la memoria, la acción motora, las funciones vegetativas centrales, el control de procesos cognitivos auomáticos y la tolerancia al estrés. Descritos inicialmente por Huber, desde una aproximación fenomenológica, forman parte de las manifestaciones más precoces de la esquizofrenia, a lo largo de cuyo curso pueden adquirir diferente

<sup>☆</sup> Please cite this article as: Miret S, Fatjó-Vilas M, Peralta V, Fañanás L. Síntomas básicos en la esquizofrenia, su estudio clínico y relevancia en investigación. Rev Psiquiatr Salud Mental (Barc.). 2016;9:111–122.

\* Corresponding author.

E-mail address: [smiret@gss.scs.es](mailto:smiret@gss.scs.es) (S. Miret).

evolución. Su presentación durante la fase prodromica de la enfermedad, para cuya evaluación han sido desarrollados diferentes instrumentos, constituye (junto con los criterios *ultra-high risk*) una de las 2 principales aproximaciones para su caracterización, lo que permite definir estados clínicos de riesgo para el desarrollo de psicosis. En la presente revisión se ofrece una visión actualizada del concepto de síntomas básicos, subrayando su potencial valour a la hora de establecer correlatos neurobiológicos de interés en la investigación etiopatogénica.

© 2015 SEP y SEPB. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

## Introduction

Over the past 20 years there has been increasing interest in the study of the early stages of schizophrenia and advances in the characterisation and knowledge of the clinical expression of the disorder, even from its prodromal phases. This has major implications in terms of the detection of the disorder and early intervention.<sup>1-11</sup>

The diagnostic characterisation of schizophrenic psychoses has been fundamentally underpinned by studying its clinical symptomatology, and the core description of the disorder has converged into a constellation of symptoms focusing on so-called positive and negative symptoms which, subsequently and from a dimensional approach, would extend into disorganized, affect, motor and cognitive symptoms.<sup>12</sup> This is borne out by the operational criteria adopted in the various diagnostic systems which have appeared in recent years. One of the most recent and representative examples of these are the DSM-5 criteria for the disorder.<sup>13</sup>

It is probable that the major reason behind this fact is that the abovementioned clinical symptomatology enables a clinical *objective* for study to be established. An analysis of the reasons behind this development goes beyond the purpose of this article, but, from a historical perspective, one only needs to refer to Cromwell's<sup>14</sup> observation that psychopathology has traditionally been described in terms of a subject's "deviations" from the norms and expectations of their social group. Thus, in relation to the more or less disruptive or "threatening" nature of the disease, "tolerable" manifestations—principally behavioural deficits—and "intolerable manifestations"—principally clinical symptoms—can be distinguished. In fact, research undertaken thus far follows these same lines, essentially focussing on the "intolerable" manifestations, whereas the more "subtle" and "inoffensive" manifestations (such as alterations in the processing of information and cognitive deficits, amongst others) have been largely underestimated or ignored.<sup>15</sup> This trend has been addressed in recent years through the study of cognitive deficits<sup>7,16,17</sup> and other symptomatic domains, such as negative symptoms<sup>18-20</sup> and their impact on functionality.<sup>7,12,21</sup>

Similar reasoning might be applied to the set of manifestations in the incipient stages of the disorder, which are frequently expressed as complaints or psychological distress with relatively non-specific and insidious characteristics.<sup>22</sup> In this regard, the description of the

prodromal manifestations of the disease has progressed from the initial retrospective studies of first psychotic episodes<sup>23,24</sup> to the establishment of criteria to identify individuals at high risk of transition to psychosis, (at-risk mental state; *ultra-high risk* [UHR]).<sup>25</sup> In recent years, to some extent, to some extent the predominant approach in characterising these stages.

However, particularly if we look at the order of the more subjective manifestations, a complementary approach to characterising prodromal symptomatology, as well as an important body of research, are to be found in the study of abnormal subjective experiences and, specifically, in the conceptual framework of the so-called *basic symptoms*, developed in Germany by Gerd Huber and the Bonn school.<sup>26,27</sup> The phenomenological approach that these authors introduce will contribute towards better clinical profiling of those most at risk of developing psychosis, and towards the study of possible underlying neurobiological correlates of pathophysiological or aetiological interest.

The objective of this review is to offer an updated vision of the concept of the basic symptoms and their expression and assessment in schizophrenia, taking into account their contribution from a phenomenological perspective. Furthermore, we shall review their relevance in characterising the prodromal stage of the disorder and their predictive value for the development of the disease.

## A brief historical overview

The first thorough attempt to describe and research patients' subjective experiences can be attributed to Jaspers, who was followed by other members of the Heidelberg school (Gruhle, Mayer-Gross, and Schneider). Based on Husserl's Phenomenology, Jaspers establishes a "return to the things themselves"—his *phenomenological method*. His objective was to intuitively capture the "essence" of the patients' subjective and experiential world, without imposing any prior theoretical framework—which would have to be "understood" and "explained" subsequently. Thus the development of phenomenological psychopathology, although frequently undervalued despite its epistemological wealth, is a descriptive method of real interest in the study of subjective experiences and in understanding the sense of a disease, in this case, schizophrenia.<sup>28</sup>

The study of the *abnormal subjective experiences* of schizophrenia is part of this tradition, although to some

extent its scope overlaps and extends to self-disturbances (*Ich Störungen*). Through the works of authors such as Minkowsky and Blankenburg, these anomalies have been reconceptualised more recently as a core aspect of the disorder as demonstrated by approaches which would imply a disturbed pre-reflexive self-consciousness,<sup>29–31</sup> or include metacognitive aspects.<sup>32</sup>

Furthermore, the origins of the current distinction of the premorbid, prodromal and psychotic stages of schizophrenia<sup>33</sup> lie in the attention paid by some authors at the time to the precursor syndromes and to the initial manifestations of the disorder. Here, Conrad's<sup>34</sup> description of "incipient schizophrenia" is worth mentioning, and his attempt to demonstrate the connection between the different phenomena of the schizophrenic experience, both in its prodromal forms and subsequent stages of development.

In turn, the phenomenological school of Bonn, lead by Gerd Huber, was to contribute essential ideas on the characterisation of the prodromal symptomatology of the psychoses.<sup>35,36</sup> Along these same lines, the works of Gross, Süllwold<sup>37</sup> and Klosterkötter are worth noting, and to a lesser extent, those of other Anglo-American authors.<sup>23,24</sup>

Huber's model of basic "substrate-close" psychotic symptoms is fundamentally based on long-term cohort studies of defectual patients. Huber establishes the concept of "basic symptoms" which are hypothetically neurobiological "substrate-close" (*Substratnahe Basissymptome*), as follows<sup>26</sup>:

"Psychotic symptoms presenting in schizophrenic patients as primary subjective experiences that constitute the basis of complex psychotic symptoms and that can be supposed to be found closer to the neurobiological substrate. They are, therefore, negative symptoms, characterised as complaints by the patients which, from a phenomenological point of view, broadly coincide with premonitory and pre-psychotic prodromal symptoms and which, in the reversible basic stages and the irreversible pure defectual syndrome are perceived and expressed as deficiencies, shortcomings or disorders."

Thus, Huber underlines the primary and, largely, subjective nature of these manifestations, whereas observable behaviour would constitute a secondary, coping, response to them. The catamnetic studies of Heidelberg and Bonn enable the various typologies and developmental possibilities of the basic symptoms to be outlined, and their structural location to be determined from a phenomenal point of view.<sup>26,36,38,39</sup>

## Basic symptoms in schizophrenia: concept, characterisation and psychopathological relationships

The "basic symptoms", also known as *anomalous subjective experiences* (because they are not observable externally and refer to non-psychotic alterations of experience), consist of subtle, subclinical complaints principally of volition, affect, thinking and language (speech), (body)perception, memory, motor action, central vegetative functions, control of automatic cognitive processes, and stress tolerance.<sup>27,40–42</sup>

By definition, these are complaints which are experienced subjectively and, although they are sometimes difficult to describe, are recognised as anomalies by the patients themselves, which distinguishes them from the positive and the negative symptoms.

The basic symptoms are the earliest symptoms which the patient experiences subjectively. However, they can occur in all stages of the disease, as pre-psychotic syndromes, in the prodromal phase of the first psychotic episode, in the prodromes of relapse, in residual states or even during the same psychotic episode, although their assessment and self-assessment in the latter case is hindered by the prominence of the symptoms themselves.<sup>42</sup> Although potentially reversible, the symptoms would constitute an essential component of the prodromal and residual stages, and can be considered to be the most immediate symptomatic expression of the neurobiological substrate of the disease. Hence their being termed "basic" and the essential nature of the disorder, over which productive psychotic symptoms would fluctuate.<sup>40,43</sup>

Taking the original concept into account, the early symptoms of the psychosis will evolve in 3 forms or levels of development<sup>40,42</sup>:


- i. Level 1 or "non-specific". Complaints principally of volition, affect, concentration and memory.
- ii. Level 2 or "specific". Qualitatively different complaints, particularly referring to the area of thought, language, bodily perception and motor action.
- iii. Level 3. Psychotic symptoms as such, including first rank Schneiderian symptoms.

These levels of development, which have been shown to be potentially reversible, demonstrate the existence of a continuum at a psychopathological level. Thus a particular somatic hallucination (level 3), could revert to a coenesthetic feeling (level 2) and this, in turn, to a non-specific somatic feeling (level 1).<sup>40</sup>

The overall developmental sequence of the basic symptoms varies (Fig. 1).<sup>40,42</sup> After the onset of level 1 symptoms, symptoms tend to increase in number and severity until psychotic symptoms present. However, occasionally, basic level 1 or 2 symptoms can improve temporarily or even remit before the symptomatic threshold is reached. These symptomatic phases without conversion to psychosis can imitate prodromal stages, known as *outpost syndromes* because they announce subsequent real prodromes.<sup>36</sup> In fact, these first manifestations can precede the first psychotic manifestations by about 10 years.<sup>40</sup>

Furthermore, the emergence of level 2 symptoms or their conversion to level 3 might be triggered by everyday situations and would exceed the already vulnerable capacity for processing information. These symptoms can be compensated for as long as they do not outweigh the personal resources or strategies of the patient, and therefore they can go unnoticed by others. Otherwise the subject might start to demonstrate avoidance behaviours, isolation behaviour or other functional deficits.

Following the first frank episode, the basic symptoms can evolve into 3 categories or *post-symptomatic basic stages*:



**Figure 1** Model of Huber's concept of basic symptoms.

Adapted from Schultze-Lutter<sup>42</sup> (2009).

- (i) A reversible post-symptomatic basic stage, characterised by complete remission of the basic symptoms.
- (ii) A prodromal stage of relapse, which might evolve into a second episode from an asymptomatic or paucisymptomatic stage.
- (iii) An irreversible post-symptomatic basic stage or *pure defectual syndrome*, with the presence of basic symptoms level 1 and 2, principally, volition, affect, cognitive and stress tolerance, with functional repercussions.

The fact that there can be an overlap, which is difficult to distinguish in a strict sense and from a phenomenological point of view, between the manifestations of the 4 stages described (precursor or advanced syndromes, prodromes, basic post-symptomatic reversible stage and pure defectual syndrome) led the authors to refer to the basic stages in the *broad sense*,<sup>26,40</sup> as opposed to the basic symptoms in the *strict sense* (basic symptoms present after an acute phase which remit over the course of a few weeks or months).

The basic symptoms constitute, therefore, an integral part of the psychoses, and they can present throughout the different stages of the disease.<sup>42</sup> Considerable prevalence of the symptoms has been demonstrated.<sup>44</sup>

Their relationship with various psychopathological aspects of the disorder has been examined, including the Schneiderian and the Bleulerian typologies,<sup>45</sup> positive and negative schizophrenia,<sup>46</sup> different neuropsychological deficits,<sup>47</sup> different psychopathological dimensions,<sup>48,49</sup> psychotic symptomatology in different stages of the disease<sup>50</sup> or their dimensional structure already in the prodromal stage.<sup>51</sup>

Although the basic symptoms would not be specific to schizophrenia and might present in other conditions, such as mood disorders,<sup>44,52</sup> some of them, especially those belonging to the cognitive and perceptual sphere, would appear to demonstrate greater specificity for the development of a psychosis,<sup>53,54</sup> although this specificity has been downplayed in subsequent re-analyses.<sup>55</sup>

## Examination and assessment instruments

Various instruments have been designed in order to assess the presence of basic symptoms. The Bonn scale for the assessment of basic symptoms (*Bonner Skala für die Beurteilung von Basissymptomen*)<sup>56</sup> and the Frankfurt Complaint Questionnaire (*Frankfurter Beschwerdefragebogen*)<sup>37</sup> have been the most widely used, in our environment as well.<sup>57-59</sup> By way of an example, and to show their content and structure, some of the 98 items of the third version of the Frankfurt Complaint Questionnaire are given in Table 1, which can be grouped according to two structures, either by scale or by dimensional factor.<sup>37,58,60</sup>

Other, less frequently used instruments are the Intentionality Scale (*IntentionalitätsSkala, Insko*),<sup>61</sup> the Frankfurt Well-being Scale (*Frankfurter BefindlichkeitsSkala*),<sup>62</sup> and the Günzburg Self Assessment Scale of Basic Symptoms (*Günzburger Selbstbeurteilungsskala für Basissymptome*).<sup>63</sup>

Furthermore, in the genealogy and the progressive development of instruments for the assessment of the prodromal symptoms of the psychoses, it is worth including those which establish their criteria from the presence, total or partial, of certain basic symptoms, as we shall detail below.<sup>64</sup>

**Table 1** Estructure and content of the Frankfurt Complaint Questionnaire version 3.

Structure in scales	Examples of items
Loss of control, LC (8 items)	I'm no longer in proper control of what I say or do.
Simple perception, SP (10 items)	Everything seems distant to me
Complex perception, CP (10 items)	I no longer clearly understand what is going on around me
Language, L (10 items)	I find it very difficult to speak or write long sentences
Cognition and thought, CT (10 items)	I find it very difficult to organise my thoughts
Memory, ME (10 items)	I find that I don't remember what I've said or done a moment earlier
Motor skills, MO (10 items)	My facial expressions are different to what I want to express
Loss of automatisms, LA (10 items)	I don't know why but anything that is not usual makes me uneasy
Anhedonia and anxiety-depression-, D (10 items)	I can no longer feel happy about anything
Sensory stimuli overload, I (10 items)	I cannot distinguish noises and everything I hear seems mixed up together
Structure by factor	
Central cognitive disorders (loss of automation)	When people use long sentences to talk to me, I find it particularly difficult to understand what they mean
F1 (11 items)	People's faces look strange to me and out of place
Perception and motor functioning	
F2 (15 items)	I'm afraid of almost everything that will happen to me throughout the day
Depressivity	When people are talking or moving around me, I find it distressing and I have to distance myself or go away to recover my inner balance
F3 (14 items)	
Internal and external overstimulation (hypervigilance, confusion)	
F4 (9 items)	
Assessment	
Award a score per item, per scale, total score and by factor. Direct scores can be turned into percentage scores, which can be interpreted according to vulnerability to schizophrenia. The items are assessed from two perspectives:	
Frequency of presentation: never/sometimes/often/always.	
Degree of complaint or distress: none/very little/some/high.	
Source: Spanish version of the questionnaire, by Peralta and Cuesta <sup>59</sup> (2003).	

## The basic symptoms in the prodromal stage and their study as risk predictors for the development of psychosis

As mentioned earlier, 2 approaches have governed research into the characterisation of the prodromal manifestations of schizophrenia: UHR and basic symptoms.<sup>65</sup>

In summary, the widely applied UHT criteria which seek to define the prodromal states which, at a symptomatic level, indicate an imminent risk of transition to psychosis, include 3 types of situations: (i) attenuated psychotic symptoms; (ii) brief limited intermittent psychotic symptoms and (iii) genetic risk and deterioration syndrome.<sup>22</sup>

The application of these criteria and the estimation of their potential predictive value in relation to the development of the disease<sup>66</sup> could be applied analogously in the characterisation of the prodromal phase established from the presence of basic symptoms, which, as mentioned earlier, constitutes the other principal approach. Using this same argument, the corresponding risk of transition to the disease could be estimated in a similar way.<sup>64,66</sup>

This section reviews the literature on the instruments which, as their selection criteria, cover the following criteria: (i) whose construct includes, totally or partially, the evaluation of items relating to the presence of basic symptoms, and (ii) which have been applied in studies in which the risk of conversion to psychosis has been estimated.

Table 2 shows the most relevant data obtained from the application of these instruments in the different studies undertaken over recent years.<sup>64,66</sup>

In general, the rates of conversion to psychosis in patient cohorts identified as being at risk of developing psychosis vary in a range of 10–50% approximately, throughout periods of follow-up from 6 months to 10 years.<sup>64</sup> A recent systematic review undertaken on prospective studies to determine the predictive validity of prodromal criteria to identify individuals at high risk of developing schizophrenia<sup>66</sup> concluded a sensitivity of 0.81 (95% CI 0.76–0.85) and a specificity of 0.67 (95% CI 0.64–0.70) for UHR criteria. When the basic symptom criteria are applied, a sensitivity of 0.98 (95% CI 0.91–1.00) and a specificity of 0.59 (95% CI 0.48–0.70) are obtained, with a positive predictive value of 0.70 and a negative predictive value of 0.96. The latter figures match the study undertaken by the Cologne Early Recognition Project,

**Table 2** Principal instruments and studies developed based on the inclusion of criteria of basic symptoms in the evaluation of prodromal symptomatology and estimations of the risk of conversion to psychosis.

Criterion/approach	Instrument, project/study	Description of the instrument and principal characteristics	Results of the principal studies: risk of conversion to psychosis		Literature
			Instrument, project/study	Rates/follow-up period	
Basic symptoms	BSABS Gross et al. (1987) <sup>56</sup>	Hetero-applied scale Structure in 6 subscales referring to 5 principal categories of basic symptoms: - Dynamic deficits (A + B) - Cognitive disturbances (C) - Coenesthetic experiences (D) - Central neurovegetative dysfunction (E) - Self-protective behaviour (F)	BSABS CER	70%/9.6 years	Klosterkötter et al. (2001) <sup>53</sup>
		Developed from cluster analysis of the results obtained in subjects in prodromal phase of the CER and patients in remission Structure in 6 subscales:	BSABS (+SIPS) EPOS	19.9%/18 months	Ruhrmann et al. (2010) <sup>67</sup>
	SPI-A  Schultze-Lutter et al. (2004) <sup>69</sup> ; Schultze-Lutter et al. (2007) <sup>70</sup>	- Dynamic affective disorders - Cognitive attention problems - Specific cognitive alterations - Self-experience disturbances - Body perception disturbances - Perceptive disturbances	BSABS (+SIPS/SOPS) DUPS SPI-A	15.6%/24 months 34.9%/20.6 months	Ziermans et al. (2011) <sup>68</sup> Schultze-Lutter et al. (2007) <sup>54</sup>
		Early Recognition and Intervention Centre (Cologne, FETZ)	SPI-A (+SIPS/SOPS) Early Recognition and Intervention Centre (Cologne, FETZ)	29%/3 years	Huang et al. (2007) <sup>71</sup>
	CER	SPI-A (+SOPS) Early Recognition and Intervention Centre (Colonia, FETZ)	SPI-A (+SOPS) Early Recognition and Intervention Centre (Munich, FETZ)	41%/5.1 years	Koethe et al. (2009) <sup>72</sup>
		SPI-A (+SIPS) Early Recognition and Intervention Centre (Munich, FETZ)	-	45%/4 years	Koutsouleris et al. (2009) <sup>73</sup>
	SPI-CY  Koch et al. (2010) <sup>74</sup> ; Schultze-Lutter et al. (2012) <sup>75</sup>	Developed from the SPI-A, considering the expression of symptomatology in infancy and parental clinical observations	-	-	Fux et al. (2013) <sup>76</sup>
		University of Heidelberg	-	-	-

**Table 2** (Continued)

Criterion/approach	Instrument, project/study	Description of the instrument and principal characteristics	Results of the principal studies: risk of conversion to psychosis		Literature
			Instrument, project/study	Rates/follow-up period	
Basic symptoms + UHR	ESI	Self-administered scale of 40 items. Developed from the BSABS, the FCQ and the SPQ	ESI (+BSABS/SIPS)	20.3%/3 years	Niessen et al. (2010) <sup>78</sup>
	Mass et al. (2000) <sup>77</sup> University Hospital Hamburg-Eppendorf				
	ERIraos	Developed from the 10 COPER items of the BSABS along with the findings of the IRAOS, SIPS, CAARMS and others	ERIraos	22.2%/18 months	Hurlemann et al. (2008) <sup>80</sup>
	Maurer et al. (2006) <sup>79</sup>	Two-step structure: - Screening interview with a pre-set cut-off point (17 items)	GRNS		
	Mannheim	- List of symptoms of incipient psychosis (110 items)	ERIraos	40.3%/32 months	Bodatsch et al. (2011) <sup>81</sup>
	GRNS		GRNS		
	BSIP	Scale of 46 items, for use in individuals attending for psychiatric care	BSIP (+ARMS criteria)	34%/25 months	Borgwardt et al. (2007) <sup>85</sup>
	Riecher-Rössler et al. (2007) <sup>82</sup>	Developed from prodromal symptoms described in the literature (DSM-III-R, ABC study) Relationship with: - BSLRP Asston et al. (2002) <sup>83</sup> - SSP	FEPSY-study		
	FEPSY-study	Müller et al. (2010) <sup>84</sup>	BSIP (+ ARMS criteria) FEPSY-study	34%/5.4 years	Riecher-Rössler et al. (2009) <sup>86</sup>
	PROD-screen	Scale of 29 items, self or hetero-applied	BSIP (+ ARMS criteria) FEPSY-study	28.6%/6 years	Gschwandtner et al. (2009) <sup>87</sup>
	Heinimaa et al. (2003) <sup>88</sup>	Developed from the BSABS, the IRAOS and the SIPS	-	-	

ARMS, at-risk mental state; BSABS, Bonn Scale for the Assessment of Basic Symptoms; BSIP, Basel Screening Instrument for Psychosis; BSLRP, Basel Screening List for Risk of Psychosis; CAARMS, Comprehensive Assessment of At-Risk Mental States; CER, Cologne Early Recognition; COPER, COgnitive-PERceptive basic symptoms; DUPs, Dutch Prediction of Psychosis Study; EPOS, European Prediction of Psychosis Study; ERIraos, Early Recognition Inventory for the Retrospective Assessment of the Onset of Schizophrenia; ESI, Eppendorf Schizophrenia Inventory; FCQ, Frankfurt Complaint Questionnaire; FEPSY, Früherkennung von Psychosen (The Basel early-detection-of-psychosis); FETZ, Früh-Erkennungs-Therapie-Zentrum für psychische Krisen (Early Recognition and Intervention Centre for Mental Crises); GRNS, German Research Network on Schizophrenia; IRAOS, Interview for the Retrospective Assessment of the Onset and course of Schizophrenia and other psychoses; PROD-screen, Prodromal Screening Symptoms of Psychosis Questionnaire; SIPS, Structured Interview for Prodromal Symptoms; SOPS, Scale of Prodromal Symptoms; SPI-A, Schizophrenia Prediction Instrument-Adult version; SPI-CY, Schizophrenia Prediction Instrument-Child and Youth version; SPQ, Schizotypal Personality Questionnaire; SSP, Self-Screen Prodrome; UHR, ultra-high risk.

The instruments and studies developed from the exclusive use of basic symptoms are distinguished from those that also contain ultra-high risk criteria in their composition.

**Table 3** Basic symptoms included in the COPER/COGDIS risk criteria.

<i>COgnitive-PERceptive basic symptoms (COPER)</i>	<i>COgnitive DISTurbances basic symptoms (COGDIS)</i>
Thought interference	Inability to divide attention
Thought perseveration	Thought interference
Thought pressure	Thought pressure
Thought block	Thought block
Receptive speech disturbance	Receptive speech disturbance
Decreased ability to discriminate between ideas/perception, fantasy/true memories	Expressive speech disturbance
Unstable ideas of reference	Unstable ideas of reference
Derealisation	Abstract thought disturbances
Visual perception disturbances (excluding hypersensitivity to light or blurred vision)	Captivation of attention by details of the visual field
Hearing perception disturbances (excluding hypersensitivity to sounds)	
Criterion: The presence of at least one of the 10 basic symptoms mentioned with an SPI-A score $\geq 3$ within the last 3 months and with an onset $\geq 12$ months	Criterion: Presence of at least 2 of the 9 basic symptoms mentioned with an SPI-A score SPI-A $\geq 3$ within the last 3 months

SPI-A, Schizophrenia Prediction Instrument-Adult version.

from the assessment of the basic symptoms using the Bonn Scale for the Assessment of Basic Symptoms (with a cut-off point determined by the presence of at least one of the 66 basic symptoms selected), where of the 160 individuals likely to be in the prodromal phase, 49.4% will develop schizophrenia over a follow-up period of 9.6 years, whereas an absence of these symptoms ruled out the subsequent development of the disorder in 96% of them.<sup>53,89</sup>

Based on these same findings and 2 other cut-off points, 2 subsets were defined that to some extent overlapped, comprising the basic symptoms showing the highest predictive value.<sup>53,54</sup> As can be seen in Table 3, these risk criteria would comprise:

- *Cognitive-perceptive basic symptom risk factors*: comprising 10 basic symptoms, relating to disturbances of cognitive-perceptive dominance, with a sensitivity of 0.87 and specificity of 0.54. These criteria were included in the Early Initial Prodromal State of the German Research Network Schizophrenia.<sup>90</sup>
- *High risk criteria relating to cognitive disturbances*: comprising the 9 cognitive basic symptoms with the highest predictive value, which were included in the European Prediction Of Psychosis Study,<sup>91</sup> with a sensitivity and specificity of around 0.67 and 0.83, respectively.

In any case, and going beyond the debate about whether defining these risk profiles might or might not be considered a diagnostic category to be taken into account in the DSM-5 or future classifications, the fact is that the most recent studies have been progressing towards the integration of both approaches. As shown in Fig. 2, the emergence of the symptoms covered under the UHR criteria and the emergence of the basic symptoms themselves would coincide in the prodromal phase, although the latter refer to the earlier phase. In consequence, the tendency has been to include both criteria, which would cover the 3 abovementioned UHR conditions (attenuated psychotic symptoms, brief intermittent psychotic symptoms and genetic risk along with decline in psychosocial functioning) as well as the basic symptoms


and certain other unspecified prodromal symptoms. This construct would thus enable criteria to be established to determine clinical psychosis high-risk states.<sup>92</sup>

Although the epidemiological estimations in the general population would require further investigation still, a verifiable fact in the population with potential prodromal symptomatology is the increased risk of suffering a psychosis in a relatively short period of time, although in percentages which do not tend to go above 40%. Therefore, this risk of transition in a population with individuals at high risk would be 17.7% after 6 months, 21.7% after one year, 29.1% after 2 years, and 35.8% at 3 years' follow-up, according to a recent meta-analysis.<sup>95</sup> To be specific, this meta-analysis concludes that the mean risk of transition to psychosis established from basic symptom criteria is 48.5% (95% CI 41.9–55.9).

Therefore the studies that would appear most promising currently would be those which present a combined, refined used of criteria.<sup>53,67,68</sup> Thus, the simultaneous presence of UHR and cognitive disturbances would appear to be associated with a greater risk of transition to psychosis, introducing a predictive model in 2 stages of risk – early and late.<sup>67</sup> In this regard, the most recently reported data using the combination of UHR criteria+cognitive disturbances would produce a risk of conversion to psychosis of 66% at 48 months' follow-up.<sup>96</sup>

## Discussion and future investigation: the basic symptoms as a marker for vulnerability to psychosis?

An initial value which can be attributed to the basic symptoms in clinical practice is precisely the fact that the distress associated with experiencing these symptoms encourages the patient to seek therapeutic help. In this regard it is obvious that the clinical investigation of these symptoms will contribute to better knowledge of their clinical and pathophysiological bases and the bases for their treatment and



**Figure 2** Model of the onset of the psychosis based on the concept of "high-risk state", with the main criteria for characterising the prodromal manifestations of the psychosis, including the basic symptoms, and the main assessment instruments. CAARMS<sup>92</sup>, comprehensive assessment of at-risk mental states; HRMS, high-risk mental state; ERraos, Early Recognition Inventory for the Retrospective Assessment of the Onset of Schizophrenia; SPI-A, Schizophrenia Prediction Instrument-Adult version. Adapted from Fusar-Poli et al.<sup>93</sup> (2013) and Rausch et al.<sup>94</sup> (2013).

intervention. A good example of this is the knowledge gained in relation to their relevance during the prodromal phase and their potential predictive value.

However, if we consider the original formulation of the basic symptoms as "hypothetically neurobiological substrate-close", it is true that after the initial studies underlining the possible role of the limbic system along with a dynamic cognitive deficit essentially attributable to a disturbance in the mechanisms for processing information,<sup>26,40</sup> research undertaken in this regard, at least to date, is somewhat scarce. Even so, in so far as the high risk states have been better integrated and characterised, it has been possible to find different neurobiological correlates in these populations on structural and functional neuroimaging.<sup>85,92,97</sup> Likewise, studies have been undertaken in which basic symptom criteria have been applied in relation to other validators, whether neurophysiological,<sup>87,98</sup> neurochemical<sup>71,72</sup> or neurocognitive<sup>47,86</sup>.

Furthermore, given the essentially cognitive nature of the basic symptoms, and similarly to the way they have been established for different cognitive deficits, more in-depth study on their possible usefulness as markers of vulnerability to the disorder is needed, as well as whether they might constitute a potential endophenotypic candidate. Some studies have been undertaken in this regard, in relation to their presentation in first degree relatives<sup>99–102</sup> and in the general, non-psychotic population.<sup>103</sup>

Finally, and from a phenomenological point of view, the way the list of basic symptoms extends to self-disturbance

should be considered, and how it can be integrated with the most recent explanatory models of the illness.<sup>104,105</sup>

Future research in this direction will doubtless contribute towards a better knowledge of the constitutive elements of the disorder, and towards improved interventions.

## Conflict of interests

The authors have no conflict of interests to declare.

## Acknowledgements

To Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM.

To the Comissionat per a Universitats i Recerca del DIUE of the Regional Government of Catalonia (2014SGR1636).

## References

1. Edwards J, McGorry PD, editors. Implementing early intervention in psychosis. A guide to establishing early psychosis services. London: Martin Dunitz; 2002.
2. Zipursky RB, Schulz SC, editors. The early stages of schizophrenia. Washington, DC: American Psychiatric Publishing; 2002.
3. Stone WS, Faraone SV, Tsuang MT, editors. Early clinical intervention and prevention in schizophrenia. Totowa: Humana Press; 2004.
4. Vázquez-Barquero JL, Crespo-Facorro B, editors. Las fases iniciales de las enfermedades mentales: Nuevos enfoques para

- la intervención en primeros episodios de psicosis. Barcelona: Elsevier Masson; 2008.
5. Jackson PD, McGorry PD. The recognition and management of early psychosis. A preventive approach. 2nd ed. Cambridge: Cambridge University Press; 2009.
  6. French D, Shiers D, Smith J, Reed M, Rayne M, editors. Promoting recovery in early psychosis: a practice manual. London: Wiley-Blackwell; 2010.
  7. Bernardo M, Bioque M, Parellada M, Saiz Ruiz J, Cuesta MJ, Llerena A, et al. Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). *Rev Psiquiatr Salud Ment.* 2013;6:4–16.
  8. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. *BMJ.* 2013;18:346.
  9. Segarra R, editor. Abordaje integral de las fases iniciales de las psicosis. Una visión crítica. Madrid: Editorial Médica Panamericana; 2014.
  10. Bernardo M, Bioque M. ¿Qué hemos aprendido de la investigación en primeros episodios psicóticos? *Rev Psiquiatr Salud Ment.* 2014;7:61–3.
  11. McGorry PD. Early intervention in psychosis: obvious, effective, overdue. *J Nerv Ment Dis.* 2015;203:310–8.
  12. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts". Part 4: Clinical features and conceptualization. *Schizophr Res.* 2009;110:1–23.
  13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
  14. Cromwell RL. Attention and information processing: a formulation for understanding schizophrenia. In: Wynne LC, Cromwell RL, Mathysse S, editors. *The nature of schizophrenia.* New York: Wiley; 1978.
  15. Ruiz-Vargas JM. Psicología cognitiva y esquizofrenia: una aproximación teórica. In: Castilla del Pino C, Ruiz-Vargas JM, editors. *Aspectos cognitivos de la esquizofrenia.* Madrid: Trotta; 1991.
  16. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. *Neuropsychology.* 2009;23:315–36.
  17. Bozikas VP, Andreou C. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. *Aust N Z J Psychiatry.* 2011;45:93–108.
  18. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. *Schizophr Bull.* 2006;32:214–9.
  19. Bobes J, Arango C, Garcia-Garcia M, Rejas J, CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. *J Clin Psychiatry.* 2010;71:280–6.
  20. Garcia-Portilla MP, Bobes J. Ante el nuevo reto de identificar el síndrome negativo de la esquizofrenia. *Rev Psiquiatr Salud Ment.* 2013;6:141–3.
  21. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? *Am J Psychiatry.* 1996;153:321–30.
  22. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. *Schizophr Bull.* 1996;22:353–70.
  23. Chapman J. The early symptoms of schizophrenia. *Br J Psychiatry.* 1966;112:225–51.
  24. Varsamis J, Adamson JD. Early schizophrenia. *Can Psychiatr Assoc J.* 1971;16:487–97.
  25. Yung AR, Phillips L, McGorry PD. Treating schizophrenia in the prodromal phase. London: Taylor & Francis; 2004.
  26. Huber G. [The concept of substrate-close basic symptoms and its significance for the theory and therapy of schizophrenic diseases] German. *Nervenarzt.* 1983;54:23–32.
  27. Klosterkötter J, Ebel H, Schultze-Lutter F, Steinmeyer EM. Diagnostic validity of basic symptoms. *Eur Arch Psychiatry Clin Neurosci.* 1996;246:147–54.
  28. Burgy M. The concept of psychosis: historical and phenomenological aspects. *Schizophr Bull.* 2008;34:1200–10.
  29. Parnas J, Moller P, Kircher T, Thalbitzer J, Jansson L, Handest P, et al. EASE: examination of anomalous self-experience. *Psychopathology.* 2005;38:236–58.
  30. Mundt CH. Anomalous self-experience: a plea for phenomenology. *Psychopathology.* 2005;38:231–5.
  31. Parnas J, Sass LA. The structure of self-consciousness in schizophrenia. In: Gallagher S, editor. *The Oxford handbook of the self.* New York: Oxford University Press; 2011.
  32. Mishara AL, Lysaker PH, Schwartz MA. Self-disturbances in schizophrenia: history, phenomenology, and relevant findings from research on metacognition. *Schizophr Bull.* 2014;40:5–12.
  33. Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. *Schizophr Bull.* 1996;22:241–56.
  34. Conrad K. Die beginnende Schizophrenie. Versuch einer Gestaltanalyse des Wahns. Stuttgart: Thieme; 1958.
  35. Huber G. Reine defektsynrome und basisstadien endogener psychosen. *Fortschr Neurol Psychiatr.* 1966;34:409–26.
  36. Huber G, Gross G, Schuttler R, Linz M. Longitudinal studies of schizophrenic patients. *Schizophr Bull.* 1980;6:592–605.
  37. Süllwold L. Frankfurter Beschwerde-Fragebogen (3). In: Süllwold L, Huber G, editors. *Schizophrener Basisstörungen.* Berlin: Springer; 1986.
  38. Huber G. Langzeitbehandlung endogener psychosen. In: Freyhan FA, Petrilowitsch N, Pichot P, editors. *Klinische psychopharmakologie*, vol. 1. Basel: Karger; 1968.
  39. Gross G, Huber G. Psychopathology of basic stages of schizophrenia in view of formal thought disturbances. *Psychopathology.* 1985;18:115–25.
  40. Gross G. The basic symptoms of schizophrenia. *Br J Psychiatry.* 1989;155:21–5.
  41. Gross G, Huber G. The true onset of schizophrenia in its meaning for the view of the disorder. *Neurol Psychiatry Brain Res.* 1996;4:93–102.
  42. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. *Schizophr Bull.* 2009;35:5–8.
  43. Huber G, Gross G. The concept of basic symptoms in schizophrenic and schizoaffective psychosis. *Recenti Prog Med.* 1989;80:646–52.
  44. Peralta V, Cuesta MJ. Subjective experiences in psychotic disorders: diagnostic value and clinical correlates. *Compr Psychiatry.* 1998;39:11–5.
  45. Peralta V, Cuesta MJ. Schneiderian versus Bleulerian schizophrenia and basic symptoms. *Psychopathology.* 1991;24:151–7.
  46. Peralta V, Cuesta MJ, de Leon J. Positive versus negative schizophrenia and basic symptoms. *Compr Psychiatry.* 1992;33:202–6.
  47. Cuesta MJ, Peralta V, Juan JA. Abnormal subjective experiences in schizophrenia: its relationships with neuropsychological disturbances and frontal signs. *Eur Arch Psychiatry Clin Neurosci.* 1996;246:101–5.
  48. Yon V, Loas G, Brien D. Subjective experiences and the psychopathological dimensions in schizophrenia. *Psychiatry Res.* 2005;137:93–102.
  49. Kim JH, Byun HJ, Ann JH, Lee J. Relationship between subjective experiences and psychopathological dimensions in schizophrenia. *Aust N Z J Psychiatry.* 2010;44:952–7.

50. Comparelli A, de Carolis A, Emili E, Rigucci S, Falcone I, Corigliano V, et al. Basic symptoms and psychotic symptoms: their relationships in the at risk mental states, first episode and multi-episode schizophrenia. *Compr Psychiatry*. 2014;55:785–91.
51. Schultze-Lutter F, Steinmeyer EM, Ruhrmann S, Klosterkötter J. The dimensional structure of self-reported prodromal disturbances in schizophrenia. *Clin Neuropsychiatry*. 2008;5:140–50.
52. Schultze-Lutter F, Ruhrmann S, Picker H, von Reventlow HG, Brockhaus-Dumke A, Klosterkötter J. Basic symptoms in early psychotic and depressive disorders. *Br J Psychiatry*. 2007;191:s31–7.
53. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. *Arch Gen Psychiatry*. 2001;58:158–64.
54. Schultze-Lutter F, Klosterkötter J, Picker H, Steinmeyer EM, Ruhrmann S. Predicting first-episode psychosis by basic symptom criteria. *Clin Neuropsychiatry*. 2007;4:11–22.
55. Peralta V, Cuesta MJ. Can schizophrenia be diagnosed in the initial prodromal phase? *Arch Gen Psychiatry*. 2002;59:664–5.
56. Gross G, Huber G, Klosterkötter J, Linz M. Bonner Skala für die Beurteilung von Basissymptomen-BSABS. Berlin: Springer; 1987.
57. Peralta V, Cuesta MJ. Subjective experiences in schizophrenia: a critical review. *Compr Psychiatry*. 1994;35:198–204.
58. Jimeno N, Jimeno A, Vargas ML. El síndrome psicótico y el Inventory de Frankfurt: conceptos y resultados. Barcelona: Springer-Verlag Ibérica; 1996.
59. Peralta V, Cuesta MJ. Inventario Psicopatológico de Frankfurt. Pamplona: H. Virgen del Camino; 2003. In: Süllwold L, Huber G, editors. Schizophrener Basisstörungen. Berlin: Springer; 1986. Adaptación española de: Süllwold L. Frankfurter Beschwerde-Fragebogen [3].
60. Cuesta MJ, Peralta V, Irigoyen I. Factor analysis of the Frankfurt Complaint Questionnaire in a Spanish sample. *Psychopathology*. 1996;29:46–53.
61. Mundt C, Fiedler P, Pracht B, Retting R. [InSka (Intentionality Scale)—a new psychopathometric instrument for the detection of schizophrenic residual symptoms] German. *Nervenarzt*. 1985;56:146–9.
62. Süllwold L, Herrlich J. Frankfurter Befindlichkeits Skala (FBS). Berlin: Springer; 1987.
63. Blumenthal S, Bell V, Neumann NU, Vogel R, Schüttler R. [Development of an instrument for operational assessment of basic symptoms in schizophrenic patients. The Günzburg Self Assessment Scale of Basic Symptoms] German. *Nervenarzt*. 1989;60:338–43.
64. Daneault JG, Stip E, Refer-O-Scope Group. Genealogy of instruments for prodrome evaluation of psychosis. *Front Psychiatry*. 2013;4:25.
65. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: assessment instruments. *Acta Psychiatr Scand*. 2006;113:273–82.
66. Chuma J, Mahadun P. Predicting the development of schizophrenia in high-risk populations: systematic review of the predictive validity of prodromal criteria. *Br J Psychiatry*. 2011;199:361–6.
67. Ruhrmann S, Schultze-Lutter F, Salokangas RK, Heinimaa M, Linszen D, Dingemans P, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the Prospective European Prediction of Psychosis Study. *Arch Gen Psychiatry*. 2010;67:241–51.
68. Ziermans TB, Schothorst PF, Sprong M, van Engeland H. Transition and remission in adolescents at ultra-high risk for psychosis. *Schizophr Res*. 2011;126:58–64.
69. Schultze-Lutter F, Klosterkötter J. Schizophrenia Prediction Instrument. Adult version (SPI-A). Cologne: University of Cologne; 2004.
70. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J. Schizophrenia Proneness Instrument. Adult version (SPI-A). Roma: Giovanni Fioriti Editore; 2007.
71. Huang JT, Leweke FM, Tsang TM, Koethe D, Kranaster L, Gerth CW, et al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. *PLoS ONE*. 2007;2:e756.
72. Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, et al. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. *Br J Psychiatry*. 2009;194:371–2.
73. Koutsouleris N, Schmitt GJ, Gaser C, Bottlender R, Scheuererker J, McGuire P, et al. Neuroanatomical correlates of different vulnerability states for psychosis and their clinical outcomes. *Br J Psychiatry*. 2009;195:218–26.
74. Koch E, Schultze-Lutter F, Schimmelmann BG, Schimmelmann G, Resch F. On the importance and detection of prodromal symptoms from the perspective of child and adolescent psychiatry. *Clin Neuropsychiatry*. 2010;7:38–48.
75. Schultze-Lutter F, Marshall M, Koch E. Schizophrenia Proneness Instrument. Child and Youth Version, Extended English Translation (SPI-CY EET). Roma: Giovanni Fioriti Editore; 2012.
76. Fux L, Walger P, Schimmelmann BG, Schultze-Lutter F. The Schizophrenia Proneness Instrument, Child and Youth version (SPI-CY): practicability and discriminative validity. *Schizophr Res*. 2013;146:69–78.
77. Mass R, Haasen C, Wolf K. [The Eppendorf Schizophrenia Inventory (ESI). Development and evaluation of a questionnaire for assessment of characteristic self perception of cognitive dysfunctions by schizophrenic patients] German. *Nervenarzt*. 2000;71:885–92.
78. Niessen MA, Dingemans PM, van de Fliert R, Becker HE, Nieman DH, Linszen D. Diagnostic validity of the Eppendorf Schizophrenia Inventory (ESI): a self-report screen for ultra-high risk and acute psychosis. *Psychol Assess*. 2010;22:935–44.
79. Maurer K, Hörrmann F, Trendler G, Schmidt G, Häfner H. Identification of psychosis risk by the Early Recognition Inventory (ERIraos) – description of the schedules and preliminary results on reliability and validity of the checklist. *Nervenheilkunde*. 2006;25:11–6.
80. Hurlemann R, Jessen F, Wagner M, Frommann I, Ruhrmann S, Brockhaus A, et al. Interrelated neuropsychological and anatomical evidence of hippocampal pathology an the at-risk mental state. *Psychol Med*. 2008;38:843–51.
81. Bodatsch M, Ruhrmann S, Wagner M, Müller R, Schultze-Lutter F, Frommann I, et al. Prediction of psychosis by mismatch negativity. *Biol Psychiatry*. 2011;69:959–66.
82. Riecher-Rössler A, Gschwandtner U, Aston J, Borgwardt S, Drewe M, Fuhr P, et al. The Basel early-detection-of-psychosis (FEPSY)-study—design and preliminary results. *Acta Psychiatr Scand*. 2007;115:114–25.
83. Aston J, Gschwandtner U, Riecher-Rössler A. Liste d'évaluation pour le dépistage précoce de la schizophrénie au cabinet du généraliste. *Forum Med Suisse*. 2002;41:971–4.
84. Müller M, Vetter S, Buchli-Kammermann J, Stieglitz R-D, Stettbacher A, Riecher-Rössler A. The Self-screen-Prodrome as a short screening tool for pre-psychotic states. *Schizophr Res*. 2010;123:217–24.
85. Borgwardt SJ, Riecher-Rössler A, Dazzan P, Chitnis X, Aston J, Drewe M, et al. Regional gray matter volume abnormalities in the at risk mental state. *Biol Psychiatry*. 2007;61:1148–56.
86. Riecher-Rössler A, Pflüger MO, Aston J, Borgwardt SJ, Brewer WJ, Gschwandtner U, et al. Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up. *Biol Psychiatry*. 2009;66:1023–30.
87. Gschwandtner U, Pflueger MO, Semenin V, Gaggiotti M, Riecher-Rössler A, Fuhr P. EEG: a helpful tool in the prediction of psychosis. *Eur Arch Psychiatry Clin Neurosci*. 2009;259:257–62.

88. Heinimaa M, Salokangas RK, Ristkari T, Plathin M, Huttunen J, Ilonen T, et al. PROD-screen—a screen for prodromal symptoms of psychosis. *Int J Methods Psychiatr Res.* 2003;12:92–104.
89. Schultze-Lutter F, Ruhrmann S, Klosterkötter J. Can schizophrenia be predicted phenomenologically? In: Johannessen JO, Martindale B, Cullberg J, editors. *Evolving psychosis. Different stages, different treatments.* London, New York: Routledge; 2006. p. 104–23.
90. Häfner H, Maurer K, Ruhrmann S, Bechdolf A, Klosterkötter J, Wagner M, et al. Early detection and secondary prevention of psychosis: facts and visions. *Eur Arch Psychiatry Clin Neurosci.* 2004;254:117–28.
91. Klosterkötter J, Ruhrmann S, Schultze-Lutter F, Salokangas RK, Linszen D, Birchwood M, et al. The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. *World Psychiatry.* 2005;4:161–7.
92. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M, et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. *Aust N Z J Psychiatry.* 2005;39:964–71.
93. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rössler A, Schultze-Lutter F, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. *JAMA Psychiatry.* 2013;70:107–20.
94. Rausch F, Eifler S, Esser A, Esslinger C, Schirmbeck F, Meyer-Lindenberg A, et al. The Early Recognition Inventory ERInraos detects at risk mental states of psychosis with high sensitivity. *Compr Psychiatry.* 2013;54:1068–76.
95. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. *Arch Gen Psychiatry.* 2012;69:220–9.
96. Schultze-Lutter F, Klosterkötter J, Ruhrmann S. Improving the clinical prediction of psychosis by combining ultra-high risk criteria and cognitive basic symptoms. *Schizophr Res.* 2014;154:100–6.
97. Mechelli A, Riecher-Rössler A, Meisenzahl EM, Tognin S, Wood SJ, Borgwardt SJ, et al. Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. *Arch Gen Psychiatry.* 2011;68:489–95.
98. Van Tricht MJ, Ruhrmann S, Arns M, Müller R, Bodatsch M, Velthorst E, et al. Can quantitative EEG measures predict clinical outcome in subjects at Clinical High Risk for psychosis? A prospective multicenter study. *Schizophr Res.* 2014;153:42–7.
99. Wieneke A, Schultze-Lutter F, Steinmeyer EM, Klosterkötter J. Abnormal subjective experiences and neuropsychological deficits in first-degree relatives of schizophrenics. *Schizophr Res.* 1997;24:49.
100. Maggini C, Raballo A. Subjective experience of schizotypic vulnerability in siblings of schizophrenics. *Psychopathology.* 2004;37:23–8.
101. Bove EA. Cognitive performance and basic symptoms in first-degree relatives of schizophrenic patients. *Compr Psychiatry.* 2008;49:321–9.
102. Miret S, Fatjó-Vilas M, Peralta V, Fañanás L. Psychotic-like experiences, basic symptoms and schizotypy in first episode schizophrenia and their first degree relatives: preliminary results. *Schizophr Res.* 2008;102:s228.
103. Meng H, Schimmelmann BG, Koch E, Bailey B, Parzer P, Günter M, et al. Basic symptoms in the general population and in psychotic and non-psychotic psychiatric adolescents. *Schizophr Res.* 2009;111:32–8.
104. Nelson B, Whitford TJ, Lavoie S, Sass LA. What are the neurocognitive correlates of basic self-disturbance in schizophrenia? Integrating phenomenology and neurocognition. Part 1 (Source monitoring deficits). *Schizophr Res.* 2014;152:12–9.
105. Nelson B, Whitford TJ, Lavoie S, Sass LA. What are the neurocognitive correlates of basic self-disturbance in schizophrenia? Integrating phenomenology and neurocognition. Part 2 (Aberrant salience). *Schizophr Res.* 2014;152:20–7.